• Disclaimer
  • Privacy Policy
Media Coverage
  • Analyst Ratings
  • Market coverage
  • Business news
  • Wealth
  • Stock Markets
  • World Economy
  • About Us
    • About us
    • Contact
No Result
View All Result
  • Analyst Ratings
  • Market coverage
  • Business news
  • Wealth
  • Stock Markets
  • World Economy
  • About Us
    • About us
    • Contact
No Result
View All Result
Media Coverage
No Result
View All Result
Home World Economy

Hedge Funds Show Interest in AngioDynamics Despite Underwhelming Earnings Report

Elaine Mendonça by Elaine Mendonça
April 17, 2023
in World Economy
0
Dividends stock investing
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

AngioDynamics (NASDAQ:ANGO) had an underwhelming quarterly earnings report, missing the consensus estimate of ($0.01) by ($0.02) with a reported loss per share of ($0.03). The medical instruments supplier’s revenue for the quarter was $80.70 million, falling short of analyst estimates of $83.20 million, but an improvement of 9.1% compared to the same quarter last year.

Despite this lackluster performance, several hedge funds have shown interest in AngioDynamics’ stock, having recently bought and sold shares of the company. Notably, CWM LLC lifted its stake in the firm by 1,048%, while State of Wyoming increased its holdings by a staggering 438.2%. In total, hedge funds and other institutional investors own nearly 95% of AngioDynamics’ stock.

As the market opened on Monday, AngioDynamics stock was selling at $9.09 per share – its 12-month low point after reaching a high mark of $24.87 per share over the past year. This dramatic shift suggests potential investor uncertainty following the less than favorable earnings report.

The medical instruments supplier currently has a market capitalization of $356.69 million and a price-to-earnings ratio of -9.67 with a beta factor sitting at 0.61 – all factors to consider when examining AngioDynamics as an investment opportunity.

Furthermore, it is worth noting that the company has a robust current ratio of 2.19 and quick ratio of 1:28, indicating strong financial health and liquidity needed to sustain continued growth in revenue and profits.

In conclusion, while AngioDynamics may have stumbled slightly during their latest quarterly report; numerous investors still view the company as having great value with room for growth potential at its current position based on their recent purchases and subsequent remarks made via public filings. As such, while undergoing growing pains, prospects remain bright for the medical instruments supplier.

AngioDynamics Faces Projected Earnings Hit in 2023



Medical equipment supplier AngioDynamics, Inc. (NASDAQ:ANGO) has taken a hit in its projected earnings for the full year 2023, according to market analysts. A report from Zacks Research reveals that the firm’s FY2023 earnings per share may reach ($0.06), down from the previous estimate of $0.01. This has led to a consensus estimate for AngioDynamics’ current full-year earnings being set at ($0.05) per share.

AngioDynamics has been subjected to other reports which have lead Raymond James and StockNews.com to drop score ratings on the supplier specifically after Price target became prevalent among different analysts over the past few months with very disparity ranges as high as $14 by Raymond James with others setting it at $22.

In another development, Senior Vice President Dave Helse sold 4,633 shares on January 31st at an average price of $12.95 amounting to a total value of around $59,997.35 putting insiders ownership down to 4.90% but this move had no considerable effect in the stock’s upward momentum.

Despite these setbacks, AngioDynamics remains one of the key players in the medical equipment supply industry and is likely to continue playing an important role in the market going forward due to its reputation for providing high-quality products and services that are trusted by medical professionals and patients alike.

Investors in this field count on keeping abreast of various targets until setting their own ideas while angiodinamics’ vision still revolves around improving patient outcomes through innovation in peripheral vascular technologies.

Despite investors potentially revise their position on either their score ratings or even keeping skeptical notions waiting for more indicators notably after two wrong quarters dictated by apparently weak fundamentals; One can not undermine Angiodynamics’ commitment to ultimate products usages targeting optimal patient benefits whether concerns were posed about product line responsiveness( repurposing already available devices for the fight against covid-19) or financials.

Tags: ANGO
Previous Post

American Public Education Misses Earnings Expectations, Finds Support from Director’s Bold Move

Next Post

Arch Capital Group Exceeds Analyst Expectations in Latest Quarterly Earnings Report

Next Post
Dividends stock news

Arch Capital Group Exceeds Analyst Expectations in Latest Quarterly Earnings Report

Wealth

Sugarhill Ddot’s Net Worth: Inside The Career of the Rising Drill Rap Star

by Gabriel Bello Obando
November 10, 2023
0

When it comes to the hip-hop scene in America, there are a few names that stand out. However, one name...

Read more

From Telenovelas to Hollywood: Exploring Kate del Castillo Net Worth and Career Achievements

June 1, 2023

Adamari López Net Worth: An Inspirational Tale of Resilience Beyond The Screen

June 1, 2023

Simon Helberg Net Worth: A Multi-Talented Hollywood Star

June 1, 2023

Sam Bailey Net Worth: Her Journey to Fame and Musical Career

June 1, 2023

Categories

  • Analyst Ratings
  • Business
  • Business news
  • Market coverage
  • Pre-IPO & Startups
  • Stock Markets
  • Wealth
  • World Economy

About Us

Our team of experienced journalists and industry experts is committed to providing you with the latest and most accurate information on a wide range of topics, from finance and technology to politics and the economy.

We are proud to be part of the Best Stocks team and to offer our readers exceptional content that is informed by our combined expertise. We look forward to continuing to serve our readers and to playing a key role in the world of business analysis and reporting.

READ MORE

  • Media Contacts
  • Journalist Contacts
  • Contact
  • About us
  • Disclaimer
  • Privacy Policy

© 2023 Media Coverage

No Result
View All Result
  • Analyst Ratings
  • Market coverage
  • Business news
  • Wealth
  • Stock Markets
  • World Economy
  • About Us
    • About us
    • Contact

© 2023 Media Coverage